Does having CML make me more likely to develop other types of cancer?

There has been no conclusive evidence that CML causes one to be more susceptible to develop other cancers. An important study undertaken at MD Anderson, which looked at secondary cancer development in patients with CML and myeloproliferative neoplasms being treated with Tyrosine Kinase Inhibitors (TKIs), concluded the following:

In conclusion, second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. Analyzed in the context of the underlying lifetime risk of developing cancer by the general population and in patients who survive cancer, no evidence at the moment suggests that exposure to TKIs is carcinogenic. Continued long-term monitoring of these patients and reporting of any patients who develop second cancers are warranted to further define any possible longer-term risks.*

There are a number of epidemiological studies in progress that are analyzing both the incidence and prevalence of different cancers in families, geographic regions, cultures, occupations, etc. It will be interesting to learn of their results as they become available. Stay in touch with new research findings on the National CML Society's website and facebook page.

*Reference: Malignancies Occurring During Therapy with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Blood. 2011 October 20; 118(16): 4353–4358. Prepublished online 2011 August 16. doi:  10.1182/blood-2011-06-362889 

For a full text version of this article, see the US National Library of Medicine link HERE

Article from Blood published here courtesy of The American Hematology Association.